Clinical Trials on Ureteral Neoplasms

Total 106708 results

Dr Anders Ullén
Bayer; Pierre Fabre Laboratories; Nordic Urothelial Cancer Oncology Group

Completed

Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR)

Bladder Cancer | Urothelial Carcinoma | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

Denmark, Sweden
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Metastatic Urethral Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Ureter Cancer AJCC v7 | Stage IV Urethral Cancer AJCC v7 | Ureter Urothelial Carcinoma and other conditions

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute

Completed

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Carcinoma, Transitional Cell | Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

United States
Altor BioScience
National Cancer Institute (NCI)

Unknown

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
Asan Medical Center
Korean Cancer Study Group

Unknown

Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma (FOCUS)

Transitional Cell Carcinoma | Bladder Cancer | Ureter Cancer | Urethral Cancer

Korea, Republic of
Cardiff University

Completed

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Ureter Cancer | Urethral Cancer

United Kingdom
Matthew Milowsky, MD
Hoosier Cancer Research Network; Bladder Cancer Advocacy Network (BCAN®)

Completed

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Bladder Cancer | Urothelial Carcinoma | Urethral Cancer | Cancer of the Ureter

United States
European Organisation for Research and Treatment...
National Cancer Institute (NCI); Medical Research Council; NCIC Clinical Trials... and other collaborators

Completed

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

France, Spain, Canada, United States, Denmark, Poland, Belgium, Germany, Netherlands, Italy, United Kingdom, Austria, Australia, Hungary, Slovakia, Israel
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Netherlands, Spain, United Kingdom, Poland, Belgium, Denmark, Hungary, Germany, Israel, Italy, Austria
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Hospital del Mar

Unknown

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Spain
European Organisation for Research and Treatment...

Completed

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Spain, France, Belgium, Israel, Switzerland, Netherlands, Italy
Dr Anders Ullén

Completed

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function (VINGEM)

Bladder Cancer | Urothelial Carcinoma | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

Denmark, Sweden
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Italy
European Organisation for Research and Treatment...

Completed

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Netherlands
UNICANCER

Completed

Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

France
Cardiff University

Completed

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
Cardiff University

Completed

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Pfizer

Completed

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Medical Research Council

Completed

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Canada, United Kingdom, Norway, New Zealand, Netherlands, South Africa, Brazil, Finland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
National Cancer Institute (NCI)

Completed

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditions

United States
University of Chicago
National Cancer Institute (NCI)

Recruiting

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States, South Africa
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

Kidney Cancer | Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
University of California, Davis
Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Recurrent Bladder Carcinoma | Stage III Urethral Cancer | Stage IV Urethral Cancer | Urethral Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage III Bladder Urothelial Carcinoma | Recurrent Urothelial Carcinoma of... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Recurrent Bladder Cancer | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral Cancer | Urethral Cancer Associated With Invasive Bladder Cancer | Localized Transitional Cell Cancer... and other conditions
Wake Forest University Health Sciences
Pfizer

Terminated

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Urinary Bladder Neoplasms | Ureteral Neoplasms | Urethral Neoplasms

United States
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral Cancer

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States, Puerto Rico, South Africa
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
Hamad Medical Corporation

Recruiting

Semi-rigid Ureteroscopy Versus Flexible Ureteroscopy For the Treatment of Proximal Ureteric Stone

Ureteric Stone | Stone Ureter

Qatar
Hans Bahlmann
Linkoeping University

Recruiting

Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery (SMILe)

Renal Cancer | Ureter Cancer | Other Specified Disorders of Kidney and Ureter | Benign Neoplasm of Ureter | Calculus of Kidney and Ureter | Ureteric Reflux | Congenital Ureteric Anomaly | Benign Renal Neoplasm

Sweden
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditions

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Adenocarcinoma of the Bladder | Distal... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III... and other conditions

United States, Canada
Fox Chase Cancer Center

Recruiting

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

Renal Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma | Ureter Cancer | Urethral Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico

Clinical Trials on Ureteral Neoplasms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations